top of page

Nanocrine joins Strategic Ventures Family

22 May 2024

May 2024
SV Special Update: Nanocrine joins Strategic Ventures Family

The latest addition to SV’s portfolio of impactful engagements, NanocrineTM is a biotech company that provides a next-generation platform for life sciences research and discovery. With its patented Plasmonic Chip technology, Nanocrine pioneers a new era in breakthrough medicine by visualizing real-time live cell signaling.

Nanocrine’s innovative approach has far-reaching implications across diverse fields including neurodegenerative disease, stem cell renewal and differentiation, cardiovascular disease, viral pathogenesis, and cancer metastasis.

Visit their website at or reach out to Mitchell Hauser to learn more about Nanocrine’s game-changing approach.

bottom of page